as on November 5, 2025 at 2:29 am IST
Day's Low
Day's High
0.48%
Downside
3.37%
Upside
52 Week's Low
52 Week's High
26.92%
Downside
96.09%
Upside
Check Akebia Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$562.1M
EPS (TTM)
-0.02
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-7.78
Industry PE ratio
-0.8126129032258065
PEG Ratio
0EBITDA
23.3M
Revenue (TTM)
203.7M
Profit Margin
-17.91%
Return On Equity TTM
-553.45%
Track how Akebia Therapeutics Inc P/E has moved over time to understand its valuation trends.
Akebia Therapeutics Inc in the last 5 years
Lowest (-68.44x)
September 30, 2025
Today (-7.78x)
November 5, 2025
Industry (-0.81x)
November 5, 2025
Highest (-0.49x)
September 30, 2022
Today’s Price to Earnings Ratio: -7.78x
Compare market cap, revenue, PE, and other key metrics of Akebia Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $562.1M | -16.06% | -7.78 | -17.91% | |
| BUY | $18.8B | NA | 16.59 | 40.65% | |
| BUY | $41.8B | NA | 21.32 | 13.81% | |
| BUY | $14.2B | 42.73% | 33.88 | 15.95% | |
| BUY | $64.0B | -27.17% | 24.89 | 27.83% |
The Akebia Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Akebia Therapeutics Inc investment value today
Current value as on today
₹1,17,179
Returns
₹17,179
(+17.18%)
Returns from Akebia Therapeutics Inc Stock
₹11,828 (+11.83%)
Dollar Returns*
₹5,351 (+5.35%)
Based on 9 analysts
88.89%
Buy
11.11%
Hold
0.00%
Sell
Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Akebia Therapeutics Inc. Average target price of $6.8
Get share price movements and forecasts by analysts on Akebia Therapeutics Inc.
What analysts predicted
69.41%UPSIDE
Target Price
$6.8
Current Price
$2.08
Analyzed by
9 Analysts
Target
$6.80
Akebia Therapeutics Inc target price $6.8, a slight upside of 69.41% compared to current price of $2.08. According to 9 analysts rating.
Search interest for Akebia Therapeutics Inc Stock has increased by 39% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:39% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Revenue is up for the last 4 quarters, 37.42M → 62.47M (in $), with an average increase of 15.5% per quarter
Best in 3 Years
![]()
In the last 3 years, AKBA has outperformed top 5 stocks with highest market-cap in its industry
Against Peers
![]()
In the last 1 year, Neurocrine Biosciences Inc. has given 17.8% return, outperforming this stock by 5.4%
Profit Down
![]()
Netprofit is down for the last 2 quarters, 6.11M → 247.0K (in $), with an average decrease of 96.0% per quarter
Price Dip
![]()
In the last 1 month, AKBA stock has moved down by -26.1%
| Organisation | Akebia Therapeutics Inc |
| Headquarters | 245 First Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Mr. John P. Butler MBA |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Kimberly Garko | Senior VP & Chief Technical Officer |
Mercedes Carrasco | Senior Director of Investor & Corporate Communications |
Mr. Erik John Ostrowski M.B.A. | Chief Business Officer, Senior VP, CFO & Treasurer |
Dr. Steven Keith Burke M.D. | Senior VP and Chief Research & Development Officer |
Mr. Richard C. Malabre | Chief Accounting Officer |
Ms. Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration |
Ms. Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary |
Ms. Meredith Bowman | Senior VP & Chief People Officer |
Mr. John P. Butler MBA | CEO, President & Director |
Mr. Nicholas Grund | Senior VP & Chief Commercial Officer |
Akebia Therapeutics Inc share price today is $2.08 as on at the close of the market. Akebia Therapeutics Inc share today touched a day high of $2.15 and a low of $2.07.
Akebia Therapeutics Inc share touched a 52 week high of $4.08 on and a 52 week low of $1.52 on . Akebia Therapeutics Inc stock price today i.e. is closed at $2.08,which is 49.00% down from its 52 week high and 36.84% up from its 52 week low.
Akebia Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Akebia Therapeutics Inc (AKBA) shares with as little as ₹88.615 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.15 in Akebia Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Akebia Therapeutics Inc share’s latest price of $2.08 as on November 5, 2025 at 2:29 am IST, you will get 4.8077 shares of Akebia Therapeutics Inc. Learn more about
fractional shares .
Akebia Therapeutics Inc stock has given -16.06% share price returns and 20.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?